Upcoming event

Tags

5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive disease, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Comorbidity, Cystectomy, Early recurrence patterns, EAU21, EMUC21, EORTC, ERBB2, ERCC2, ESMO21, ESOU21, ESOU22, Gene expression analysis, Guidelines, Hematuria, High-risk NMIBC, Highlight of the Month, Immune checkpoint, Immune checkpoint blockade, Immunoregulation, Immunotherapy, Intravesical therapy, Laparoscopic radical cystectomy, Masterclass, Masterclass on MIBC, Masterclass on NMIBC, Meta-analysis, Metastatic urothelial cancer, MIBC, Microscopic haematuria, Molecular subtypes, Multiparametric MRI, Neoadjuvant, Neoadjuvant chemotherapy, Neoplasm recurrence, Nephroureterectomy, NIBC, Non-visible haematuria, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, PD-L1, Pembrolizumab, PET, PLND, Postoperative complications, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, Surgical video, Surgical videos, Systematic review, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, Urinary bladder neoplasms, Urinary diversion, Urological surgery, Urothelial cancer, Urothelium, UROwebinar, UTUC, Webinar
Show all

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial

The LANCET Oncology, April 2022

Results of the intracorporeal robotic vs open cystectomy (iROC) multi-centre randomised trial

Propensity matched comparison of radical cystectomy with trimodality therapy for muscle invasive bladder cancer (MIBC): a multi-institutional study

Real-world performance of MRI after TURBT in predicting final pathologic outcomes in bladder cancer

Two-year efficacy follow-up of a phase I trial of intravesical BCG combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous BCG treatment

Evaluating intravesical nadofaragene firadenovec and immune checkpoint blockade combination therapy in BCG-unresponsive non-muscle-invasive bladder cancer: evidence from a phase 3 trial

Final clinical results of pivotal trial of IL-15RaFc superagonist N-803 with BCG in bcg-unresponsive non-muscle invasive bladder cancer (NMIBC) cis and papillary cohorts

Neoadjuvant Pembrolizumab May Result in Long-term outcome improvement in biomarker-unselected patients with Muscle-Invasive Bladder Cancer: Updated results from PURE-01

Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report

Journal of Urology, April 2022

Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial

Journal of Clinical Oncology, March 2022

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of Clinical Oncology, January 2022

A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)

Next